URMC / Research / Health Research /Clinical Trials / Study Details

Darbepoetin Trial to Improve Red Cell Mass and Neuroprotection in Preterm Infants

Research Question:
Does the drug Darbe improve cognitive function in preterm infants?

Basic Study Information

Purpose:
Study Hypothesis: Preterm infants administered weekly Darbe during the neonatal period will have improved neurocognitive outcome at 22-26 months compared to placebo

Location: University of Rochester

Study Contact Information

Study Coordinator: Carl T D'Angio, MD
Phone: (505) 272-0180
Email: rohls@salud.unm.edu

Additional Study Details

Learn More About These Conditions

More information about Premature Birth

Contact This Study

First Name *

This field is required

Middle Name

Last Name *

This field is required

Phone Number

I agree to be contacted by The University of Rochester Medical Center regarding participation in this study. *

You must agree to be contacted to continue.

Please call me during the day.

Please call me during the evening.

Message

Return to Search

Research

UR Health Research